Date: 2013-07-11
Type of information: Series B financing round
Company: Pathoquest (France)
Investors: Idinvest Partners (France) Aurinvest Capital (France) Kurma Biofund (France)
Amount: € 3,8 million
Funding type: series B financing round
Planned used: These funds will be used to support the first clinical study of a novel NGS-SaaS (Software as a Service) cloud based diagnostic assay.
Others: * On July 11, 2013, PathoQuest, a new generation molecular diagnostics company that offers a new approach based on NGS (Next Generation Sequencing) in the field of infectious diseases, has announced the closing of a new fundraising of € 3.8 million. This round brings in two new investors, Idinvest and Aurinvest, in addition to the existing investor Kurma Life Science Partners.
The company has raised € 2 million in March 2011. The additional funds will allow PathoQuest to launch the first clinical study of a novel NGS-SaaS (Software as a Service) cloud based diagnostic assay. This assay is a bioinformatics workflow that is designed to assist the diagnostic decision-making. This clinical study will target diagnosis of severe multi-etiological-based infectious episodes in immuno-compromised patients. This immuno-suppression can be congenital or acquired, whether through immuno-suppressing treatment post-transplant or through anticancer chemotherapy. PathoQuest intends to launch a first commercial product in 2015, following an extension of this clinical trial in the US in the coming months.
Therapeutic area: Diagnostic
